How the Osteoporosis Screening Recommendation Was Built

The short answer

In January 2025 the US Preventive Services Task Force (USPSTF) reaffirmed that screening for osteoporosis earns a B recommendation for all women 65 years and older, and a B for postmenopausal women younger than 65 who are at increased risk. A B grade signals moderate certainty that the practice yields moderate net benefit. For men, the Task Force issued an I statement: current evidence is insufficient to weigh benefits against harms. The recommendation was published in JAMA (2025;333(6):498-508). What follows is an appraisal of how a screening grade like this is assembled, because the single letter on the page rests on a chain of reasoning worth reading link by link.

What a screening grade is meant to say

USPSTF letter grades are not endorsements of a product or a clinic. They are summary judgments about a population-level question: if we screen asymptomatic people who feel well, does the average person come out ahead once benefits and harms are counted? A B grade means the Task Force has moderate certainty of moderate net benefit. The word certainty is doing real work there. It refers to how confident the reviewers are in the body of evidence, separate from how large the benefit is. A practice can help people yet still receive a cautious grade if the underlying studies are thin, indirect, or narrow in whom they enrolled.

For osteoporosis, the target is fragility fracture, especially of the hip. Hip fracture in an older adult is a serious event, and a preventive strategy that reduces it plausibly matters. The screening question is whether measuring bone density in people without symptoms, then acting on the result, reduces those fractures more than it harms.

Link one: does the test measure something real

The recommendation begins with the test itself. Central dual-energy x-ray absorptiometry (DXA) of the hip or lumbar spine is the reference measurement. Osteoporosis is defined by a bone mineral density at least 2.5 standard deviations below the young-adult reference, a T score of -2.5 or lower. The USPSTF evidence review found that DXA can predict fractures, with reported discrimination (area under the curve) for major osteoporotic fracture spanning roughly 0.60 to 0.80 depending on the study and outcome.

That range is instructive. A test that predicts an outcome with an AUC of 0.60 is only modestly better than a coin flip, while a value near 0.80 is meaningfully useful. Bone density is a real risk factor, but it is one input among several, and on its own it sorts people imperfectly.

Link two: from density to risk score

This is where FRAX enters. FRAX is a fracture risk calculator that combines age, sex, prior fracture, family history, smoking, glucocorticoid use, and other factors, with or without a bone density value. In the USPSTF review, FRAX for ten-year hip fracture risk in women showed AUCs of about 0.74 to 0.77 without bone density, and 0.76 to 0.79 with it. Adding the DXA number improved prediction only slightly.

That detail explains the structure of the recommendation for younger women. The Task Force advises a two-step approach: first check whether a postmenopausal woman under 65 has one or more risk factors, then apply a clinical risk assessment tool to decide whether a DXA scan is warranted. FRAX is one such tool, alongside others like OST and ORAI. The Task Force notes plainly that some of these instruments were developed on small or homogeneous populations, which limits how confidently they transfer to everyone. Risk scores organize the decision; they do not settle it.

Link three: the hardest link, does acting change outcomes

A test can be accurate and a risk score reasonable, yet the value of screening still hinges on whether the whole sequence, find low density then treat, prevents fractures. Here the evidence is more limited than many people assume. The USPSTF identified three randomized trials that tested a screening program against usual care for fracture outcomes, known as SCOOP, ROSE, and SOS, all conducted in older women in Europe. Pooled, they pointed to a reduction in hip fracture, with a relative risk near 0.83, and the review described an absolute difference on the order of a few fewer hip fractures per thousand women screened over several years.

Those are real but modest effects, drawn from a narrow slice of the world's population. The certainty attached to a B grade, rather than an A, reflects exactly this: the benefit is consistent in direction, yet the direct trial base is small and geographically limited, and it does not speak equally to all groups.

The paradox the guideline has to hold

One finding deserves emphasis because it is easy to misread. Most fragility fractures occur in people who do not meet the T score definition of osteoporosis. There are simply many more people with moderately low bone density than with severe deficits, so the larger absolute number of fractures arises from that broader group. A density threshold identifies those at highest individual risk while missing much of the population-level fracture burden. A screening program built on a threshold is therefore a triage tool, not a fracture forecast for any one person, and the guideline is careful not to promise more than the evidence supports.

Why men get an I, not a grade

The I statement for men is not a claim that screening cannot help them. It is an honest statement about a gap. The trials and much of the predictive data were generated in women, and the Task Force declined to extrapolate a net benefit it had not seen tested. An I statement is the machinery working as intended: absence of sufficient evidence is reported as absence, not filled in by assumption.

Reading the grade well

The 2025 statement is best understood as a transparent audit trail. Each link, the accuracy of DXA, the added value of FRAX, the size and reach of the treatment trials, and the paradox of where fractures actually fall, is visible in the reasoning, and each is graded for what it can and cannot support. That is what a well-built recommendation looks like: not a verdict handed down, but a chain you can inspect. For an individual, the decision to screen still belongs in a conversation with a clinician who knows the specifics. This article is educational and is not medical advice.